AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26775262 — intervention group
Group type: COMPARATOR
Intervention: Standard/existing program (no structured incentive program)
Number of subjects: 570
Study 26775262 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced goal setting linked to a structured incentive scheme
Number of subjects: 570
Study 26775262 — intervention group
Group type: COMPARATOR
Intervention: Standard/existing program
Number of subjects: 570
Study 25188543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of an exposure intervention, beginning in the emergency department shortly after trauma exposure
Number of subjects: 65
Study 25188543 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 65
Study 25188543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of an exposure intervention
Number of subjects: 65
Study 22270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamiclear formulation (copper sulfate pentahydrate and Hypericum perforatum)
Number of subjects: 149
Study 22270204 — intervention group
Group type: COMPARATOR
Intervention: 5% Acyclovir cream
Number of subjects: 149
Study 20969660 — intervention group
Group type: EXPERIMENTAL
Intervention: DGE (dermal gel extra)
Number of subjects: 140
Study 20969660 — intervention group
Group type: COMPARATOR
Intervention: NASHA (nonanimal stabilized HA)
Number of subjects: 140
Study 17950167 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior intervention
Number of subjects: 878
Study 17950167 — intervention group
Group type: COMPARATOR
Intervention: SUN protection behaviors (comparison condition)
Number of subjects: 878
Study 16302455 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine and thymol varnish
Number of subjects: 38
Study 16302455 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish containing only thymol
Number of subjects: 38
Study 12475848 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 15
Study 9665673 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2 IU/m2 for 12 months
Number of subjects: 27
Study 9665673 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 27
Study 7712610 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren drops
Number of subjects: 30
Study 7712610 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren vehicle
Number of subjects: 30
Study 7712610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellufresh (non‐preserved lubricant)
Number of subjects: 30
Study 2654285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 14
Study 2654285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 14
Study 31333215 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 294
Study 31333215 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 294
Study 31333215 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 294
Study 31333215 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 294
Study 27048345 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IFC
Number of subjects: 75
Study 27048345 — intervention group
Group type: COMPARATOR
Intervention: New placebo
Number of subjects: 75
Study 27048345 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 75
Study 26434929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulip abutment (TA) design
Number of subjects: 27
Study 26434929 — intervention group
Group type: COMPARATOR
Intervention: Standard platform abutment (SA)
Number of subjects: 27
Study 23235200 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 150
Study 23235200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21784603 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill walking (Exercise)
Number of subjects: 25
Study 21784603 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical treatment (Control)
Number of subjects: 25
Study 21784603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PAD patients and healthy adults)
Number of subjects: 25
Study 19345452 — intervention group
Group type: EXPERIMENTAL
Intervention: CH‐19 sweet pepper
Number of subjects: 27
Study 19345452 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin and green tea
Number of subjects: 27
Study 19345452 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin + green tea
Number of subjects: 27
Study 19345452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16696864 — intervention group
Group type: COMPARATOR
Intervention: Fluids alone (n = 25)
Number of subjects: 50
Study 16696864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluids and dobutamine (n = 25)
Number of subjects: 50
Study 15278085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine (4 mL 10%)
Number of subjects: 50
Study 15278085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized normal saline solution)
Number of subjects: 50
Study 11376302 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (mean daily dose: 58 ± 1 mg)
Number of subjects: 2184
Study 11376302 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean daily dose: 162 ± 1 mg)
Number of subjects: 2184
Study 11376302 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 2184
Study 11376302 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 2184
Study 9292587 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg every 4 hours (regimen A)
Number of subjects: 320
Study 9292587 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 300 mg every 12 hours (regimen B)
Number of subjects: 320
Study 8501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma infusion after heparin reversal
Number of subjects: 51
Study 8501929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no platelet rich plasma infusion)
Number of subjects: 51
Study 3682857 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial injection of protamine
Number of subjects: 68
Study 3682857 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial injection of protamine
Number of subjects: 68
Study 3682857 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic injection of protamine
Number of subjects: 68
Study 3682857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 29972818 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) continuous veno-venous hemodialysis (CVVHD)
Number of subjects: 10
Study 29972818 — intervention group
Group type: COMPARATOR
Intervention: High-flux membrane (HFM) continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 10
Study 29515279 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg b.i.d
Number of subjects: 90
Study 29515279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg b.i.d
Number of subjects: 90
Study 29515279 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg t.i.d
Number of subjects: 90
Study 26162995 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-contouring procedures (BC) including abdominoplasty (n=20), rectus plication (n=7), liposuction (n=6)
Number of subjects: 66
Study 26162995 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery (BS)
Number of subjects: 66
Study 26162995 — intervention group
Group type: COMPARATOR
Intervention: Obese group (no surgery)
Number of subjects: 66
Study 23966023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risperidone (open label) for 4 weeks
Number of subjects: 24
Study 23966023 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 24
Study 21961949 — intervention group
Group type: EXPERIMENTAL
Intervention: DiAlert lifestyle education programme
Number of subjects: 268
Study 21961949 — intervention group
Group type: COMPARATOR
Intervention: Leaflet (control group)
Number of subjects: 268
Study 21644418 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol suspension
Number of subjects: 134
Study 21644418 — intervention group
Group type: COMPARATOR
Intervention: Vaginally administered misoprostol
Number of subjects: 134
Study 16646026 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg) plus methotrexate (MTX) administered intramuscularly once weekly for 12 weeks
Number of subjects: 185
Study 16646026 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 185
Study 16646026 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg) plus methotrexate (MTX) in patients with psoriasis involving >= 3% BSA
Number of subjects: 185
Study 16646026 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX) in patients with psoriasis involving >= 3% BSA
Number of subjects: 185
Study 12825917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis-based intervention
Number of subjects: 44
Study 12825917 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 44
Study 10773503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms/kg
Number of subjects: 39
Study 10773503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 39
Study 10773503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8665115 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min at 62.5 W (mean maternal heart rate 138 beats.min‐1) (test A)
Number of subjects: 11
Study 8665115 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min at 87.5 W (mean maternal heart rate 156 beats.min‐1) (test B)
Number of subjects: 11
Study 8665115 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min at 62.5 W (mean maternal heart rate 142 beats.min‐1) (test C)
Number of subjects: 11
Study 2003533 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 333 mg three times daily
Number of subjects: 0
Study 2003533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6360586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation within the first 12 hours of birth
Number of subjects: 191
Study 6360586 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 191
Study 30517329 — intervention group
Group type: COMPARATOR
Intervention: Nylon 4.0
Number of subjects: 60
Study 30517329 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25, 4.0
Number of subjects: 60
Study 27653448 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection 500 U
Number of subjects: 369
Study 27653448 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 369
Study 27653448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 25162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (initiated at 100 µg, titrated to effective dose)
Number of subjects: 130
Study 25162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (titration phase)
Number of subjects: 130
Study 23742699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7%) inhaled twice daily for 48 weeks
Number of subjects: 25
Study 23742699 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) inhaled twice daily for 48 weeks
Number of subjects: 25
Study 23742699 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of treatment effects
Number of subjects: 25
Study 20509919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Sealant System (Pleuraseal) applied over air leak areas
Number of subjects: 46
Study 20509919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional interventions)
Number of subjects: 46
Study 17717058 — intervention group
Group type: EXPERIMENTAL
Intervention: bladed cleats
Number of subjects: 36
Study 17717058 — intervention group
Group type: EXPERIMENTAL
Intervention: elliptical firm ground cleats
Number of subjects: 36
Study 17717058 — intervention group
Group type: EXPERIMENTAL
Intervention: hard ground cleats
Number of subjects: 36
Study 17717058 — intervention group
Group type: EXPERIMENTAL
Intervention: turf cleats
Number of subjects: 36
Study 17717058 — intervention group
Group type: COMPARATOR
Intervention: all cleat types
Number of subjects: 36
Study 16368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50
Study 16368836 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study 12851021 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 20
Study 12851021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10728961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibutilide
Number of subjects: 0
Study 10728961 — intervention group
Group type: COMPARATOR
Intervention: Direct-current cardioversion
Number of subjects: 0
Study 8875098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (1,000 mg)
Number of subjects: 26
Study 8875098 — intervention group
Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 26
Study 1305392 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 32
Study 1305392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3927210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 208
Study 3927210 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 208
Study 31311577 — intervention group
Group type: EXPERIMENTAL
Intervention: I-BiT treatment
Number of subjects: 120
Study 31311577 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 120
Study 29768152 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cannabidiol group
Number of subjects: 225
Study 29768152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cannabidiol group
Number of subjects: 225
Study 29768152 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 225
Study 27142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 60
Study 27142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 60
Study 27142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 60
Study 27142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 60
Study 27142292 — intervention group
Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 60
Study 24499249 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 495
Study 24499249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 495
Study 22773262 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with existing prosthesis and fitting with SACH, SAFE, Talux, and Proprio feet
Number of subjects: 10
Study 22773262 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing prosthesis
Number of subjects: 10
Study 22773262 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprio foot
Number of subjects: 10
Study 20207340 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (8.6 mg) with docusate (50 mg)
Number of subjects: 96
Study 20207340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17439572 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cerclage
Number of subjects: 242
Study 17439572 — intervention group
Group type: COMPARATOR
Intervention: Single cerclage
Number of subjects: 242
Study 15632489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n = 21)
Number of subjects: 62
Study 15632489 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise (n = 21)
Number of subjects: 62
Study 15632489 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 62
Study 11050694 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-5 transdermal patch (5 mg GTN)
Number of subjects: 18
Study 11050694 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-10 transdermal patch (10 mg GTN)
Number of subjects: 18
Study 11050694 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-15 transdermal patch (15 mg GTN)
Number of subjects: 18
Study 9066350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Plasma Exchanges (PEs)
Number of subjects: 556
Study 9066350 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Plasma Exchanges (PEs)
Number of subjects: 556
Study 9066350 — intervention group
Group type: COMPARATOR
Intervention: 6 Plasma Exchanges (PEs)
Number of subjects: 556
Study 8373607 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal lift maneuver
Number of subjects: 102
Study 2941572 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg BID
Number of subjects: 48
Study 2941572 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg BID
Number of subjects: 48
Study 2941572 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 600 mg BID
Number of subjects: 48
Study 2941572 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 975 mg QID
Number of subjects: 48
Study 31300705 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) formula
Number of subjects: 276
Study 31300705 — intervention group
Group type: COMPARATOR
Intervention: Lower protein (LP) formula
Number of subjects: 276
Study 30267226 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot intervention group
Number of subjects: 60
Study 30267226 — intervention group
Group type: EXPERIMENTAL
Intervention: Shod intervention group
Number of subjects: 60
Study 30267226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30267226 — intervention group
Group type: COMPARATOR
Intervention: BESS test
Number of subjects: 60
Study 27625185 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample instrumental variable estimate with 10% relative bias (F parameter of 10)
Number of subjects: 0
Study 27625185 — intervention group
Group type: COMPARATOR
Intervention: One-sample setting with risk factor measurements only for control participants
Number of subjects: 0
Study 27625185 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample setting with risk factor data on both control and case participants
Number of subjects: 0
Study 23737941 — intervention group
Group type: EXPERIMENTAL
Intervention: Water depth of 0.45 m and water speed of 0.4 m/s
Number of subjects: 76
Study 23737941 — intervention group
Group type: EXPERIMENTAL
Intervention: Water depth of 0.90 m and water speed of 0.8 m/s
Number of subjects: 76
Study 23737941 — intervention group
Group type: EXPERIMENTAL
Intervention: Water depth of 0.90 m and water speed of 1.2 m/s
Number of subjects: 76
Study 23737941 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience with rip currents and tropical cyclones
Number of subjects: 76
Study 21999871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 to 30 mg)
Number of subjects: 56
Study 21999871 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (0.5 to 4.0 mg)
Number of subjects: 56
Study 18471513 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenously every 6 hours, doubled on day 4 if SCr did not decrease by 30%)
Number of subjects: 112
Study 18471513 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 112
Study 18471513 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 112
Study 18471513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 16199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with COPD, BMI 30 kg/m²
Number of subjects: 642
Study 16199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with COPD, FEV(1)%FVC<median
Number of subjects: 642
Study 16199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with COPD, increasing daily number of cigarettes by 10
Number of subjects: 642
Study 16199147 — intervention group
Group type: COMPARATOR
Intervention: Men with COPD
Number of subjects: 642
Study 16199147 — intervention group
Group type: COMPARATOR
Intervention: Women with COPD
Number of subjects: 642
Study 14756934 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow experience
Number of subjects: 0
Study 14756934 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of favorite activities
Number of subjects: 0
Study 10709160 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral lansoprazole for 7 days
Number of subjects: 18
Study 10709160 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 18
Study 10709160 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluations including adverse events, vital signs, clinical laboratory determinations, ECG, and physical examinations
Number of subjects: 18
Study 9329355 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant GH replacement therapy for 6 months (period 1)
Number of subjects: 0
Study 9329355 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement for 12 months
Number of subjects: 0
Study 9329355 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 0
Study 9329355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 8479462 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin (0.1 percent retinoic acid cream)
Number of subjects: 54
Study 8479462 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 54
Study 3079487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (including diethylstilbestrol, estramustine phosphate, aminoglutethimide, progestational agents, antiandrogens, orchiectomy, LHRH analogues like leuprolide, and combination hormonal therapies)
Number of subjects: 0
Study 30326808 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thrust spine mobilisations
Number of subjects: 6
Study 30326808 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior thrust spine mobilisations
Number of subjects: 6
Study 27740724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase treatment
Number of subjects: 73